Suppr超能文献

膦酸盐和磷酸盐的前药:跨越膜屏障

Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

作者信息

Wiemer Andrew J, Wiemer David F

机构信息

Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, 06269, USA.

出版信息

Top Curr Chem. 2015;360:115-60. doi: 10.1007/128_2014_561.

Abstract

A substantial portion of metabolism involves transformation of phosphate esters, including pathways leading to nucleotides and oligonucleotides, carbohydrates, isoprenoids and steroids, and phosphorylated proteins. Because the natural substrates bear one or more negative charges, drugs that target these enzymes generally must be charged as well, but small charged molecules can have difficulty traversing the cell membrane by means other than endocytosis. The resulting dichotomy has stimulated a great deal of effort to develop effective prodrugs, compounds that carry little or no charge to enable them to transit biological membranes, but able to release the parent drug once inside the target cell. This chapter presents recent studies on advances in prodrug forms, along with representative examples of their application to marketed and developmental drugs.

摘要

新陈代谢的很大一部分涉及磷酸酯的转化,包括通向核苷酸和寡核苷酸、碳水化合物、类异戊二烯和类固醇以及磷酸化蛋白质的途径。由于天然底物带有一个或多个负电荷,靶向这些酶的药物通常也必须带电,但带小电荷的分子通过内吞作用以外的方式穿过细胞膜可能会有困难。由此产生的二分法激发了人们为开发有效的前药付出巨大努力,这些化合物几乎不带电荷或不带电荷,使其能够穿过生物膜,但一旦进入靶细胞就能释放母体药物。本章介绍了前药形式进展的最新研究,以及它们应用于上市药物和研发中药物的代表性实例。

相似文献

1
Prodrugs of phosphonates and phosphates: crossing the membrane barrier.
Top Curr Chem. 2015;360:115-60. doi: 10.1007/128_2014_561.
2
Synthesis of phosphoramidate prodrugs: ProTide approach.
Curr Protoc Nucleic Acid Chem. 2013 Jun;Chapter 15:15.5.1-15.5.15. doi: 10.1002/0471142700.nc1505s53.
4
Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates.
Antimicrob Agents Chemother. 1993 Oct;37(10):2247-50. doi: 10.1128/AAC.37.10.2247.
6
New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity.
Bioorg Med Chem. 2017 Sep 1;25(17):4637-4648. doi: 10.1016/j.bmc.2017.06.046. Epub 2017 Jul 6.
7
Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro.
J Infect Dis. 2005 Feb 1;191(3):396-9. doi: 10.1086/426831. Epub 2004 Dec 29.
8
Prodrugs of biologically active phosphate esters.
Bioorg Med Chem. 2003 Mar 20;11(6):885-98. doi: 10.1016/s0968-0896(02)00552-7.

引用本文的文献

1
Improved Synthesis of a Sub-Nanomolar Vinyl Phosphonate Inhibitor of Dehydroquinate Synthase.
Molecules. 2025 Sep 3;30(17):3594. doi: 10.3390/molecules30173594.
3
Synthesis and evaluation of triazole-containing aryl/acyloxy prodrugs of a BTN3A1 ligand.
Eur J Med Chem. 2025 Apr 5;287:117345. doi: 10.1016/j.ejmech.2025.117345. Epub 2025 Feb 1.
4
Mild and Chemoselective Triethylsilane-Mediated Debenzylation for Phosphate Synthesis.
Org Lett. 2025 Jan 10;27(1):246-251. doi: 10.1021/acs.orglett.4c04258. Epub 2024 Dec 24.
5
The Interactions of Anti-HIV Pronucleotides with a Model Phospholipid Membrane.
Molecules. 2024 Dec 7;29(23):5787. doi: 10.3390/molecules29235787.
6
Harnessing Oxetane and Azetidine Sulfonyl Fluorides for Opportunities in Drug Discovery.
J Am Chem Soc. 2024 Dec 25;146(51):35377-35389. doi: 10.1021/jacs.4c14164. Epub 2024 Dec 12.
7
Enhanced Plasma Stability and Potency of Aryl/Acyloxy Prodrugs of a BTN3A1 Ligand.
ACS Med Chem Lett. 2024 Sep 25;15(10):1771-1777. doi: 10.1021/acsmedchemlett.4c00371. eCollection 2024 Oct 10.
8
Cytotoxicity of phosphoramidate, bis-amidate and cycloSal prodrug metabolites against tumour and normal cells.
RSC Med Chem. 2024 Apr 18;15(6):1973-1981. doi: 10.1039/d4md00115j. eCollection 2024 Jun 19.
9
Progress in phosphorylation of natural products.
Mol Biol Rep. 2024 May 27;51(1):697. doi: 10.1007/s11033-024-09596-1.
10
Genetic Encoding of Phosphorylated Amino Acids into Proteins.
Chem Rev. 2024 May 22;124(10):6592-6642. doi: 10.1021/acs.chemrev.4c00110. Epub 2024 May 1.

本文引用的文献

1
Synthesis and in Vitro Evaluation of a Peptidomimetic Inhibitor Targeting the Src Homology 2 (SH2) Domain of STAT6.
ACS Med Chem Lett. 2013 Dec 4;5(1):69-72. doi: 10.1021/ml4003919. eCollection 2014 Jan 9.
2
Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV Infection.
ACS Med Chem Lett. 2010 Dec 17;2(2):130-5. doi: 10.1021/ml100209f. eCollection 2011 Feb 10.
3
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):340-8. doi: 10.1097/QAI.0000000000000172.
5
ProTides of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents.
Bioorg Med Chem. 2014 May 1;22(9):2816-24. doi: 10.1016/j.bmc.2014.02.056. Epub 2014 Mar 15.
6
PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
Eur J Med Chem. 2014 May 6;78:259-68. doi: 10.1016/j.ejmech.2014.03.051. Epub 2014 Mar 17.
7
The DiPPro approach: synthesis, hydrolysis, and antiviral activity of lipophilic d4T diphosphate prodrugs.
ChemMedChem. 2014 Apr;9(4):762-75. doi: 10.1002/cmdc.201300500. Epub 2014 Mar 11.
8
Bisphosphonate prodrugs: synthesis and biological evaluation in HuH7 hepatocarcinoma cells.
Eur J Med Chem. 2014 Apr 22;77:56-64. doi: 10.1016/j.ejmech.2014.02.054. Epub 2014 Feb 23.
9
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
N Engl J Med. 2014 Jan 16;370(3):211-21. doi: 10.1056/NEJMoa1306218.
10
Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.
Angew Chem Int Ed Engl. 2014 Jan 3;53(1):199-204. doi: 10.1002/anie.201307387. Epub 2013 Nov 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验